[
    {
        "id": "osp-47419",
        "type": "article-journal",
        "title": "Transforming growth factor-β3 relation with osteoporosis and osteoporotic fractures",
        "author": [
            {
                "family": "Haghighizadeh",
                "given": "Ebrahim"
            },
            {
                "family": "Shahrezaee",
                "given": "Mostafa"
            },
            {
                "family": "Sharifzadeh",
                "given": "Seyyed Reza"
            },
            {
                "family": "Momeni",
                "given": "Mitra"
            }
        ],
        "URL": "https://omanscience.com/ar/articles/transforming-growth-factor-3-relation-with-osteoporosis-and-osteoporotic-fractures",
        "language": "en",
        "issued": {
            "date-parts": [
                [
                    2019
                ]
            ]
        },
        "container-title": "Journal of Research in Medical Sciences",
        "volume": "24",
        "issue": "1",
        "page": "46",
        "DOI": "10.4103/jrms.jrms_1062_18",
        "publisher": "Wolters Kluwer Medknow Publications",
        "ISSN": "1735-1995",
        "abstract": "Background: The high socioeconomic impact of osteoporosis and osteoporotic fracture is due to their high mortality, morbidity, and disease-related costs. Nowadays, bone mineral density (BMD) is a comparatively expensive way to diagnose and follow up patients with osteoporosis. Transforming growth factor-β3 (TGF-β3) is a protein categorized into cytokines. Some previous in vitro studies showed TGF-β3 effects on osteocytes and bone formation. Therefore, we conducted this study to find if there is any significant relationship between TGF-β3 and BMD results. Materials and Methods: This was an analytical cross-sectional study conducted in 2017. We included individuals who had been referred from their physicians to undergo BMD dual-energy X-ray absorptiometry. Blood samples were taken from 150 participants for measuring TGF-β3 with ELISA method. Results: The mean ± standard deviation of TGF-β3 serum level was 79 ± 30.8 pg/ml (minimum 41 pg/ml and maximum 210 pg/ml). There was a statistically significant and direct proportional relationship between TGF-β3 and T-score as a marker for the diagnosis and follow-up of osteoporosis and osteoporotic fracture ( P = 0.001) (Pearson's correlation = +0.95). Conclusion: There was a significant relationship between TGF-β3 serum level and BMD. TGF-β3 serum level may be used as a marker for the diagnosis and follow-up of osteoporosis and osteoporotic fracture."
    }
]